...
首页> 外文期刊>Journal of Medicinal Chemistry >Dual Probes for the Dopamine Transporter and σ_1 Receptors: Novel Piperazinyl Alkyl-bis(4'-fluorophenyl)amine Analogues as Potential Cocaine-Abuse Therapeutic Agents
【24h】

Dual Probes for the Dopamine Transporter and σ_1 Receptors: Novel Piperazinyl Alkyl-bis(4'-fluorophenyl)amine Analogues as Potential Cocaine-Abuse Therapeutic Agents

机译:多巴胺转运蛋白和σ_1受体的双重探针:新型哌嗪基烷基双(4'-氟苯基)胺类似物作为可卡因滥用的潜在治疗剂

获取原文
获取原文并翻译 | 示例

摘要

Both dopamine uptake inhibitors and σ_1 receptor antagonists have been implicated as potential pharmacotherapeutics for the treatment of cocaine abuse. While the dopamine uptake inhibitors may share with cocaine neurochemical mechanisms underlying reinforcing properties, σ_1 antagonists have been shown to attenuate some behavioral actions and toxic side effects associated with cocaine overdose. Rimcazole, a σ_1 receptor antagonist that binds to the DAT (K_i = 225 nM), is not behaviorally cocaine-like and attenuates some of the behavioral actions of cocaine. To determine the roles of both DAT and σ_1 receptors in the behavioral actions of rimcazole, a series of analogues was synthesized. Initial studies identified two analogues (1 and 4)that showed high to moderate affinities for both DAT and σ_1 receptors and failed to show cocaine-like discriminative stimulus (DS) effects. A second series of bis(4'-fluorophenyl)-amine analogues have now been prepared in which the most potent DAT compound, 19 (K_i = 8.5 nM), was selective over serotonin transporter (SERT/DAT = 94), norepinephrine transporter (NET/DAT = 63), and σ_1 receptor binding (σ_1/DAT = 44). In addition, two other analogues 10 and 17 showed superior selectivity for DAT over SERT (170- and 140-fold, respectively) and DAT over NET (219- and 190-fold, respectively) but were essentially equipotent at DAT and σ_1 receptors (10; K_i = 77 and 124 nM, respectively, 17; K_i = 28 and 13 nM, respectively). CoMFA studies at both DAT and σ_1 receptors were performed to examine structural requirements for optimal binding at these two targets as well as to assess differences between them. Behavioral evaluation of analogues with varying affinities for both DAT and σ_1 receptors may provide a novel approach toward designing medications for cocaine abuse.
机译:多巴胺摄取抑制剂和σ_1受体拮抗剂都被认为是可卡因滥用的潜在药物治疗药物。尽管多巴胺摄取抑制剂可能与可卡因具有潜在的增强作用的神经化学机制共有,但已证明σ_1拮抗剂可减轻与可卡因过量有关的某些行为作用和毒性副作用。里卡唑是与DAT结合的σ_1受体拮抗剂(K_i = 225 nM),在行为上并非可卡因样,并减弱了可卡因的某些行为作用。为了确定DAT和σ_1受体在rimcazole的行为中的作用,合成了一系列类似物。最初的研究确定了两个类似物(1和4),它们对DAT和σ_1受体均显示出高至中度亲和力,但未显示出可卡因样的歧视性刺激(DS)效应。现在已经制备了第二系列的双(4'-氟苯基)-胺类似物,其中最有效的DAT化合物19(K_i = 8.5 nM)对血清素转运蛋白(SERT / DAT = 94),去甲肾上腺素转运蛋白( NET / DAT = 63)和σ_1受体结合(σ_1/ DAT = 44)。此外,另外两个类似物10和17对DAT的选择性优于SERT(分别为170和140倍),对DAT的选择性较对NET(分别为219和190倍)高,但在DAT和σ_1受体上具有基本等价性( 10; K_i = 77和124 nM,分别为17; K_i = 28和13 nM。进行了DAT和σ_1受体的CoMFA研究,以检查在这两个靶点上最佳结合的结构要求,并评估它们之间的差异。对DAT和σ_1受体具有不同亲和力的类似物的行为评估可能为设计可卡因滥用药物提供了一种新颖的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号